AstraZeneca Pharma India (NSE:ASTRAZEN, BOM:506820) has received board approval to surrender its factory license to the Department of Factories, Boilers, Industrial Safety and Health, India, for cancellation, according to a Wednesday filing to the Indian stock exchanges.
The license is valid from Dec. 14, 2023, to Dec. 31.
The move follows the pharmaceutical company's earlier disclosures about exiting its manufacturing site and surrendering its manufacturing license.